Search

Your search keyword '"Hecht, Jonathan L."' showing total 234 results
Start Over Author "Hecht, Jonathan L." Search Limiters Peer Reviewed
234 results on '"Hecht, Jonathan L."'

2. A genetic basis for sex differences in Xp11 translocation renal cell carcinoma

Author

Achom, Mingkee, Sadagopan, Ananthan, Bao, Chunyang, McBride, Fiona, Li, Jiao, Konda, Prathyusha, Tourdot, Richard W., Xu, Qingru, Nakhoul, Maria, Gallant, Daniel S., Ahmed, Usman Ali, O’Toole, Jillian, Freeman, Dory, Lee, Gwo-Shu Mary, Hecht, Jonathan L., Kauffman, Eric C., Einstein, David J., Choueiri, Toni K., Zhang, Cheng-Zhong, and Viswanathan, Srinivas R.

Published
2024
Full Text
View/download PDF

3. Placenta accreta spectrum care infrastructure: an evidence-based review of needed resources supporting placenta accreta spectrum care

Author

Fitzgerald, Garrett D., Newton, J.M., Atasi, Lamia, Buniak, Christina M., Burgos-Luna, Juan Manuel, Burnett, Brian A., Carver, Alissa R., Cheng, CeCe, Conyers, Steffany, Davitt, Caroline, Deshmukh, Uma, Donovan, Bridget M., Easter, Sara Rae, Einerson, Brett D., Fox, Karin A., Habib, Ashraf S., Harrison, Rachel, Hecht, Jonathan L., Licon, Ernesto, Nino, Julio Mateus, Munoz, Jessian L., Nieto-Calvache, Albaro Jose, Polic, Aleksandra, Ramsey, Patrick S., Salmanian, Bahram, Shamshirsaz, Alireza A., Shamshirsaz, Amir A., Shrivastava, Vineet K., Woolworth, Melissa B., Yurashevich, Mary, Zuckerwise, Lisa, and Shainker, Scott A.

Published
2024
Full Text
View/download PDF

7. Triaging and Evaluation of Products of Conception in Abortions and Post-Partum Hemorrhage.

Author

Katzman, Philip J. and Hecht, Jonathan L

Subjects
POSTPARTUM hemorrhage, ECTOPIC pregnancy, PLACENTA accreta, CLINICAL medicine, MOLAR pregnancy, ABORTION
Abstract

The proper evaluation of abortion specimens and placentas from stillbirth and post-partum cases is important for adequate clinical care of post-abortion and post-partum patients. The following topics will be reviewed: (1) the importance of evaluation of both fetal and placental tissue in first trimester abortions to confirm an intrauterine pregnancy versus an ectopic pregnancy; (2) the clinical history associated with an abortion specimen or retained products of conception (POC) influences how the pathologist should triage the specimen; (3) the criteria for diagnosis of a molar pregnancy, which is critical for clinicians to know which patients need follow-up; (4) the utility of genetic studies for both diagnosis and appropriate follow-up of the patient; and (5) the pathologic evaluation of specimens from patients with post-partum hemorrhage for placenta accreta spectrum and subinvolution of maternal vessels. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Special Report of the Society for Maternal-Fetal Medicine Placenta Accreta Spectrum Ultrasound Marker Task Force: Consensus on definition of markers and approach to the ultrasound examination in pregnancies at risk for placenta accreta spectrum

Author

Shainker, Scott A., Coleman, Beverly, Timor-Tritsch, Ilan E., Bhide, Amarnath, Bromley, Bryann, Cahill, Alison G., Gandhi, Manisha, Hecht, Jonathan L., Johnson, Katherine M., Levine, Deborah, Mastrobattista, Joan, Philips, Jennifer, Platt, Lawrence D., Shamshirsaz, Alireza A., Shipp, Thomas D., Silver, Robert M., Simpson, Lynn L., Copel, Joshua A., and Abuhamad, Alfred

Published
2021
Full Text
View/download PDF

13. Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques

Author

Aid, Malika, Busman-Sahay, Kathleen, Vidal, Samuel J., Maliga, Zoltan, Bondoc, Stephen, Starke, Carly, Terry, Margaret, Jacobson, Connor A., Wrijil, Linda, Ducat, Sarah, Brook, Olga R., Miller, Andrew D., Porto, Maciel, Pellegrini, Kathryn L., Pino, Maria, Hoang, Timothy N., Chandrashekar, Abishek, Patel, Shivani, Stephenson, Kathryn, Bosinger, Steven E., Andersen, Hanne, Lewis, Mark G., Hecht, Jonathan L., Sorger, Peter K., Martinot, Amanda J., Estes, Jacob D., and Barouch, Dan H.

Published
2020
Full Text
View/download PDF

19. Lifetime Exposure to Cigarette Smoke, B-Cell Tumor Immune Infiltration, and Immunoglobulin Abundance in Ovarian Tumors.

Author

Hathaway, Cassandra A., Townsend, Mary K., Tianyi Wang, Vinci, Christine, Jake-Schoffman, Danielle E., Hecht, Jonathan L., Saeed-Vafa, Daryoush, Moran Segura, Carlos, Nguyen, Jonathan V., Conejo-Garcia, Jose R., Fridley, Brooke L., and Tworoger, Shelley S.

Abstract

Background: Cigarette smoke exposure has been linked to systemic immune dysfunction, including for B-cell and immunoglobulin (Ig) production, and poor outcomes in patients with ovarian cancer. No study has evaluated the impact of smoke exposure across the life-course on B-cell infiltration and Ig abundance in ovarian tumors. Methods: We measured markers of B and plasma cells and Ig isotypes using multiplex immunofluorescence on 395 ovarian cancer tumors in the Nurses' Health Study (NHS)/NHSII. We conducted beta-binomial analyses evaluating odds ratios (OR) and 95% confidence intervals (CI) for positivity of immune markers by cigarette exposure among cases and Cox proportional hazards models to evaluate hazard ratios (HR) and 95% CI for developing tumors with low (+ among ever smokers (OR, 1.54; 95% CI, 1.14-2.07) and ever smokers with no parental smoke exposure (OR, 2.03; 95% CI, 1.18-3.49) versus never smokers. Women with parental cigarette smoke exposure versus not had higher risk of developing ovarian cancer with low IgG+ (HR, 1.51; 95% CI, 1.10-2.09), whereas ever versus never smokers had a lower risk (HR, 0.74; 95% CI, 0.56-0.99). Conclusions: Ever smoking was associated with increased odds of IgA in ovarian tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Fetal Neuropathology in Zika Virus-Infected Pregnant Female Rhesus Monkeys

Author

Martinot, Amanda J., Abbink, Peter, Afacan, Onur, Prohl, Anna K., Bronson, Roderick, Hecht, Jonathan L., Borducchi, Erica N., Larocca, Rafael A., Peterson, Rebecca L., Rinaldi, William, Ferguson, Melissa, Didier, Peter J., Weiss, Deborah, Lewis, Mark G., De La Barrera, Rafael A., Yang, Edward, Warfield, Simon K., and Barouch, Dan H.

Published
2018
Full Text
View/download PDF

34. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC)

Author

Ditzel, Helena M., Strickland, Kyle C., Meserve, Emily E., Stover, Elizabeth, Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Muto, Michael G., Liu, Joyce F., Feltmate, Colleen, Horowitz, Neil, Berkowitz, Ross S., Gupta, Mamta, Hecht, Jonathan L., Lin, Douglas I., Jochumsen, Kirsten M., Welch, William R., Hirsch, Michelle S., Quade, Bradley J., Lee, Kenneth R., Crum, Christopher P., Mutter, George L., Nucci, Marisa R., and Howitt, Brooke E.

Published
2019
Full Text
View/download PDF

39. Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade)

Author

Singh, Naveena, Hirschowitz, Lynn, Zaino, Richard, Alvarado-Cabrero, Isabel, Duggan, Maire A., Ali-Fehmi, Rouba, Euscher, Elizabeth, Hecht, Jonathan L., Horn, Lars-Christian, Ioffe, Olga, Matias-Guiu, Xavier, McCluggage, W. Glenn, Mikami, Yoshiki, Ordi, Jaume, Parkash, Vinita, Quddus, M. Ruhul, Quick, Charles M., Staebler, Annette, Zaloudek, Charles, Nucci, Marisa, Malpica, Anais, and Oliva, Esther

Published
2019
Full Text
View/download PDF

40. Endometrial Carcinoma, Grossing and Processing Issues: Recommendations of the International Society of Gynecologic Pathologists

Author

Malpica, Anais, Euscher, Elizabeth D., Hecht, Jonathan L., Ali-Fehmi, Rouba, Quick, Charles M., Singh, Naveena, Horn, Lars-Christian, Alvarado-Cabrero, Isabel, Matias-Guiu, Xavier, Hirschowitz, Lynn, Duggan, Máire, Ordi, Jaume, Parkash, Vinita, Mikami, Yoshiki, Ruhul Quddus, M., Zaino, Richard, Staebler, Annette, Zaloudek, Charles, McCluggage, W. Glenn, and Oliva, Esther

Published
2019
Full Text
View/download PDF

43. Associations between prediagnostic aspirin use and ovarian tumor gene expression.

Author

Sasamoto, Naoko, Stewart, Paul A., Wang, Tianyi, Thompson, Zachary J., Yoder, Sean J., Hecht, Jonathan L., Cleveland, John L., Conejo‐Garcia, Jose, Fridley, Brooke L., Terry, Kathryn L., and Tworoger, Shelley S.

Subjects
OVARIAN tumors, OVARIAN cancer, ASPIRIN, GENE expression, GENE expression profiling, FALSE discovery rate
Abstract

Background: Aspirin use has been associated with reduced ovarian cancer risk, yet the underlying biological mechanisms are not fully understood. To gain mechanistic insights, we assessed the association between prediagnosis low and regular‐dose aspirin use and gene expression profiles in ovarian tumors. Methods: RNA sequencing was performed on high‐grade serous, poorly differentiated, and high‐grade endometrioid ovarian cancer tumors from the Nurses' Health Study (NHS), NHSII, and New England Case–Control Study (n = 92 cases for low, 153 cases for regular‐dose aspirin). Linear regression identified differentially expressed genes associated with aspirin use, adjusted for birth decade and cohort. False discovery rates (FDR) were used to account for multiple testing and gene set enrichment analysis was used to identify biological pathways. Results: No individual genes were significantly differentially expressed in ovarian tumors in low or regular‐dose aspirin users accounting for multiple comparisons. However, current versus never use of low‐dose aspirin was associated with upregulation of immune pathways (e.g., allograft rejection, FDR = 5.8 × 10−10; interferon‐gamma response, FDR = 2.0 × 10−4) and downregulation of estrogen response pathways (e.g., estrogen response late, FDR = 4.9 × 10−8). Ovarian tumors from current regular aspirin users versus never users were also associated with upregulation in interferon pathways (FDR <1.5 × 10−4) and downregulation of multiple extracellular matrix (ECM) architecture pathways (e.g., ECM organization, 4.7 × 10−8). Conclusion: Our results suggest low and regular‐dose aspirin may impair ovarian tumorigenesis in part via enhancing adaptive immune response and decreasing metastatic potential supporting the likely differential effects on ovarian carcinogenesis and progression by dose of aspirin. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Excess placental secreted frizzled-related protein 1 in maternal smokers impairs fetal growth

Author

Wang, Alice, Zsengeller, Zsuzsanna K., Hecht, Jonathan L., Buccafusca, Roberto, Burke, Suzanne D., Rajakumar, Augustine, Weingart, Emily, Yu, Paul B., Salahuddin, Saira, and Karumanchi, S. Ananth

Subjects
Gene expression -- Observations, Fetus -- Growth, Cellular proteins -- Properties, Smoking in pregnancy -- Genetic aspects, Health care industry
Abstract

Maternal cigarette smoking during pregnancy remains one of the most common and preventable causes of fetal growth restriction (FGR), a condition in which a fetus is unable to achieve its genetically determined potential size. Even though epidemiologic evidence clearly links maternal cigarette smoking with FGR, insight into the molecular mechanisms of cigarette smoke-induced FGR is lacking. Here, we performed transcriptional profiling of placentas obtained from smoking mothers who delivered growth-restricted infants and identified secreted frizzled-related protein 1 (sFRPI), an extracellular antagonist of endogenous WNT signaling, as a candidate molecule. sFRPI mRNA and protein levels were markedly upregulated (-10fold) in placentas from smoking mothers compared with those from nonsmokers. In pregnant mice, adenovirus-mediated overexpression of sFRP1 led to FGR, increased karyorrhexis in the junctional zone, and decreased proliferation of labyrinthine trophoblasts. Consistent with our hypothesis that placental WNT signaling is suppressed in maternal smokers, we found that exposure to carbon monoxide analogs led to reduced WNT signaling, increased SFRP1 mRNA expression, and decreased cellular proliferation in a trophoblast cell line. Moreover, administration of carbon monoxide analogs to pregnant mice in late gestation led to FGR. In summary, our results indicate that the increased placental expression of sFRP1 seen in smokers impairs fetal growth by inhibiting WNT signaling and trophoblast proliferation., Introduction Fetal growth restriction (FGR), a condition in which a fetus is unable to achieve its genetically determined potential size, results in substantial perinatal and neonatal morbidity and mortality (1). [...]

Published
2015
Full Text
View/download PDF

48. Knowledge Gaps in Placenta Accreta Spectrum.

Author

Carusi, Daniela A., Duzyj, Christina M., Hecht, Jonathan L., Butwick, Alexander J., Barrett, Jon, Holt, Roxane, O'Rinn, Susan E., Afshar, Yalda, Gilner, Jennifer B., Newton, J. M., and Shainker, Scott A.

Subjects
PROFESSIONS, SOCIAL support, PLACENTA accreta, SYMPTOMS, HEALTH care teams, DISEASE management, DISEASE risk factors
Abstract

Since its first description early in the 20th Century, placenta accreta and its variants have changed substantially in incidence, risk factor profile, clinical presentation, diagnosis and management. While systematic use of diagnostic tools and a multidisciplinary team care approach has begun to improve patient outcomes, the condition's pathophysiology, epidemiology, and best practices for diagnosis and management remain poorly understood. The use of large databases with broadly accepted terminology and diagnostic criteria should accelerate research in this area. Future work should focus on non-traditional phenotypes, such as those without placenta previa–preventive strategies, and long term medical and emotional support for patients facing this diagnosis. Key Points Placenta accreta spectrum research may be improved with standardized terminology and use of large databases. Placenta accreta prediction should move beyond ultrasound with the addition of biomarkers, and needs to extend to those without traditional risk factors. Future research should identify practices that can prevent future accreta development. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Measurement of Ovarian Tumor Immune Profiles by Multiplex Immunohistochemistry: Implications for Epidemiologic Studies.

Author

Hathaway, Cassandra A., Conejo-Garcia, Jose R., Fridley, Brooke L., Rosner, Bernard, Saeed-Vafa, Daryoush, Segura, Carlos Moran, Nguyen, Jonathan V., Hecht, Jonathan L., Naoko Sasamoto, Terry, Kathryn L., Tworoger, Shelley S., and Townsend, Mary K.

Abstract

Background: Despite the immunogenic nature of many ovarian tumors, treatment with immune checkpoint therapies has not led to substantial improvements in ovarian cancer survival. To advance population-level research on the ovarian tumor immune microenvironment, it is critical to understand methodologic issues related to measurement of immune cells on tissue microarrays (TMA) using multiplex immunofluorescence (mIF) assays. Methods: In two prospective cohorts, we collected formalin-fixed, paraffin-embedded ovarian tumors from 486 cases and created seven TMAs. We measured T cells, including several sub-populations, and immune checkpoint markers on the TMAs using two mIF panels. We used Spearman correlations, Fisher exact tests, and multivariable-adjusted beta-binomial models to evaluate factors related to immune cell measurements in TMA tumor cores. Results: Between-core correlations of intratumoral immune markers ranged from 0.52 to 0.72, with more common markers (e.g., CD3+, CD3+CD8+) having higher correlations. Correlations of immune cell markers between the whole core, tumor area, and stromal area were high (range 0.69-0.97). In multivariable-adjusted models, odds of T-cell positivity were lower in clear cell and mucinous versus type II tumors (ORs, 0.13-0.48) and, for several sub-populations, were lower in older tissue (sample age > 30 versus = 10 years; OR, 0.11-0.32). Conclusions: Overall, high correlations between cores for immune markers measured via mIF support the use of TMAs in studying ovarian tumor immune infiltration, although very old samples may have reduced antigenicity. Impact: Future epidemiologic studies should evaluate differences in the tumor immune response by histotype and identify modifiable factors that may alter the tumor immune microenvironment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results